From diabetes to cancer and dementia, scientists are developing surprising new ways to spot illnesses early Engineers at in Japan are developing a device that uses tears to detect breast cancer John Naish
Tears contain markers that can be used for diagnosing a broad range of diseases
HERE’S a good reason to start crying with happiness: your tears could soon save your life by providing an early warning of cancer, diabetes and autoimmune disease.
In future, they may even predict your risk of developing Alzheimer’s. And tears are not the only bodily secretions that are being used in a new generation of painless diagnostic tests. Scientists say we can also use earwax, sweat and nasal mucus to detect everything from depression to gout.
Search jobs 10-Dec-2020 Cyrano Therapeutics Raises $12.8 Million to Complete Phase 2 Trial of CYR-064 for the Restoration of Chronic Smell and Flavor Loss
WASHINGTON, Dec. 10, 2020 /PRNewswire/ Cyrano Therapeutics, a clinical stage regenerative medicine company developing a novel intranasal therapy for smell and flavor restoration, has raised $12.8 million in a Series A financing led by Remiges Ventures and Lumira Ventures, with the participation of additional investors. The funds will be used to complete a Phase 2 clinical trial of the company s lead product, CYR-064, in the U.S. and Europe. As part of the financing, Taka Koda of Remiges Ventures and Gerry Brunk of Lumira Ventures have joined the company s board of directors.
Share this article
Share this article
WASHINGTON, Dec. 10, 2020 /PRNewswire/ Cyrano Therapeutics, a clinical stage regenerative medicine company developing a novel intranasal therapy for smell and flavor restoration, has raised $12.8 million in a Series A financing led by Remiges Ventures and Lumira Ventures, with the participation of additional investors. The funds will be used to complete a Phase 2 clinical trial of the company s lead product, CYR-064, in the U.S. and Europe. As part of the financing, Taka Koda of Remiges Ventures and Gerry Brunk of Lumira Ventures have joined the company s board of directors.
The chronic loss of smell and flavor is a condition affecting at least 5% of the population in the U.S. with a similar incidence in Europe and Asia. Influenza, allergic rhinitis and traumatic brain injury are commonly known causes of chronic smell and flavor loss. In the neurodegenerative disease sector, it is also known that 95 percent of Parkinson s patients experie